FDA’s Center for Veterinary Medicine approved Felix Pharmaceuticals Pvt. Ltd.’s ANADA for Enrofloxacin Flavored Tablets on May 21, 2020. The flavored tablets provide veterinarians with a new treatment option for disease associated with bacteria susceptible to enrofloxacin that may cause skin, urinary, respiratory and other infections. The canine and feline pilot and pivotal bioequivalence studies involved in this application were conducted by Kingfisher International Inc.
